Latest news with #GS-1482

Yahoo

FDA placed clinical hold on Gilead HIV treatment trials of GS-1720

The Food and Drug Administration has placed a clinical hold on Gilead's (GILD) HIV treatment trials of GS-1720 and/or GS-4182, the company said in a statement. The clinical hold is due to the identification of a safety signal of decreases in CD4+T-cell and absolute lymphocyte counts in a subset of participants receiving the combination of GS-1720 and GS-4182, the company explained. It added, 'Clinical trial investigators involved in the trials have been informed of these actions. GS-1720 and GS-1482 are investigational agents and have not been approved anywhere globally. We intend to investigate and pursue the potential of both agents and are committed to working with regulatory authorities to resolve the issues underlying the clinical hold. Gilead has multiple other long-acting oral and injectable investigational HIV treatment combinations under evaluation in clinical and preclinical studies, including combinations with weekly, monthly, quarterly, and twice-yearly dosing. This hold does not impact these combinations or their respective clinical or pre-clinical development programs.' Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today's best-performing stocks on TipRanks >> Read More on GILD: Disclaimer & DisclosureReport an Issue Gilead Sciences: Strong Market Position and Growth Potential Drive Buy Rating Gilead Sciences' Oncology Advancements: Trodelvy's Potential to Boost Stock Value Gilead Sciences: Promising Pipeline and Strategic Advancements Justify Buy Rating Gilead Sciences: Buy Rating Driven by Promising HIV Treatment Pipeline and Strategic Growth Prospects Gilead Sciences: Buy Rating Affirmed on Promising Oncology Pipeline and Trodelvy's Potential as New Standard of Care